(12) **Translation of European patent specification**

(11) **NO/EP 2970225 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 405/12 (2006.01)
A61K 31/336 (2006.01)
A61K 31/404 (2006.01)
A61P 37/00 (2006.01)
C07D 303/32 (2006.01)
C07D 409/12 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.11.05
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.08.15
(86)	European Application Nr.	14723553.5
(86)	European Filing Date	2014.03.14
(87)	The European Application's Publication Date	2016.01.20
(30)	Priority	2013.03.14, US, 201361785608 P 2013.03.14, US, 201361786086 P 2013.07.18, US, 201361847780 P 2013.07.22, US, 201361856847 P 2013.09.27, US, 201361883798 P 2013.09.27, US, 201361883843 P 2014.02.19, US, 201461941798 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Onyx Therapeutics, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
(72)	Inventor	MCMINN, Dustin, 255 Kent Road, Pacifica, CA 94044, USA JOHNSON, Henry, 360 Hazel Avenue, San Bruno, CA 94066, USA MOEBIUS, David, C., 804 Balboa Lane, Foster City, CA 94404, USA
(74)	Agent or Attorney	CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54) Title **DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS**

(56) References Cited:

US-A1- 2007 105 786, EVA HUBER ET AL: "Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity", CELL, CELL PRESS, US, vol. 148, no. 4, 2 December 2011 (2011-12-02), pages 727-738, XP028458988, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2011.12.030 [retrieved on 2012-01-12], WO-A2-2007/149512,

WOOIN LEE ET AL: "The Immunoproteasome: An Emerging Therapeutic Target", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 11, no. 23, 1 December 2011 (2011-12-01), pages 2923-2930, XP055129375, ISSN: 1568-0266, DOI: 10.2174/156802611798281348, M. SCREEN ET AL: "Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 51, 11 October 2010 (2010-10-11), pages 40125-40134, XP055099238, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.160606, EVAM HUBER ET AL: "Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity", CELL, CELL PRESS, US, vol. 148, no. 4, 2 December 2011 (2011-12-02), pages 727-738, XP028458988, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2011.12.030 [retrieved on 2012-01-12], S. E. VERBRUGGE ET AL: "Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 341, no. 1, 10 January 2012 (2012-01-10), pages 174-182, XP055129369, DOI: 10.1124/jpet.111.187542, TONY MUCHAMUEL ET AL: "A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis", NATURE MEDICINE, vol. 15, no. 7, 1 July 2009 (2009-07-01), pages 781-787, XP055094218, ISSN: 1078-8956, DOI: 10.1038/nm.1978

Patentkrav

1. Forbindelse med formel (II) eller et farmasøytisk akseptabelt salt av samme,



(II)

hvori:

R^2 og R^3 er hver uavhengig valgt fra C_{1-6}aralkyl og C_{1-6}heteroaralkyl; og

R^6 er valgt fra heterosyklyl og heteroaryl.

2. Forbindelse ifølge krav 1, hvori R^2 er C_{1-6}heteroaralkyl.

3. Forbindelse ifølge krav 1, hvori R^2 er C_{1-6}aralkyl.

4. Forbindelse ifølge krav 1, hvori R^3 er C_{1-6}heteroaralkyl.

5. Forbindelse ifølge krav 1, hvori R^3 er C_{1-6}aralkyl.

6. Forbindelse ifølge krav 1, hvori R^6 er heterosyklyl.

7. Forbindelse ifølge krav 1, hvori R^6 er heteroaryl.

8. Forbindelse ifølge krav 1 med en struktur valgt fra gruppen bestående av:



,



,


,

,

,

,

og


,

eller et farmasøytisk akseptabelt salt av samme.

9. Forbindelse ifølge krav 1 med en struktur valgt fra gruppen bestående av:


C-3001,


C-3002,





C-3003,



C-3005,



C-3008,



C-3009,



C-3010,

C-3011,

5



C-3012, og



C-3013,

eller et farmasøytisk akseptabelt salt av samme.

10. Forbindelse med en struktur valgt fra gruppen bestående av:



10 ,


,

,


,

,


,

,

5


C-3007,


C-3014,

10



C-3015,



C-3016,



C-3017,



C-3018, og



C-3019.

11. Farmasøytisk blanding som omfatter forbindelsen ifølge ett av kravene 1 til 10, eller et farmasøytisk akseptabelt salt av samme, og en farmasøytisk akseptabel bærer eller fortynningsmiddel.

12. Forbindelse ifølge ett av kravene 1 til 10, eller blandingen ifølge krav 11, for anvendelse i en framgangsmåte for inhibering av en immunoproteasom av en celle.

13. Forbindelse ifølge ett av kravene 1 to 10 eller blandingen ifølge krav 11 for anvendelse i inhibering av en immunoproteasom i et menneske.

14. Forbindelse for anvendelse ifølge krav 12 eller krav 13, hvori forbindelsen inhiberer LMP2-underenheten av nevnte immunoproteasom.

15. Forbindelse ifølge ett av kravene 1 to 10, eller blandingen ifølge krav 11, for anvendelse i behandlingen av en sykdom valgt fra gruppen bestående av:

(a) en immun-relatert sykdom; eller

(b) kreft; eller

(c) inflammasjon; eller

(d) infeksjon; eller

(e) proliferativ sykdom; og

(f) neurodegenerativ sykdom.